ReviewJournal of endocrinological investigation2008
The biological characterization of neuroendocrine tumors: the role of neuroendocrine markers.
Review in Journal of endocrinological investigation, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 62 citations in OpenAlex.
- Genetic insight into lung neuroendocrine tumors: Notch and Wnt signaling pathways as potential targets.Journal of translational medicine · 2025Article
- Efficacy and tolerability of somatostatin analogues according to gender in patients with neuroendocrine tumors.Reviews in endocrine & metabolic disorders · 2024Review
- Management of Functional Pancreatic Neuroendocrine Neoplasms.Current treatment options in oncology · 2023Review
- Review
- Circulating Angiogenic Markers in Gastroenteropancreatic Neuroendocrine Neoplasms: A Systematic Review.Current issues in molecular biology · 2022Review
- mRNA profiling of a well-differentiated G1 pancreatic NET correlates with immunohistochemistry profile: a case report.BMC gastroenterology · 2021Article
- Therapy of Patients with Neuroendocrine Neoplasia-Evidence-Based Approaches and New Horizons.Journal of clinical medicine · 2019Review
- ONECUT2 is a driver of neuroendocrine prostate cancer.Nature communications · 2019Article
- Hindgut gastropancreatic neuroendocrine carcinoma mimicking hydatid disease.Radiology case reports · 2018Article
- Role of contrast-enhanced ultrasound to define prognosis and predict response to biotherapy in pancreatic neuroendocrine tumors.Journal of endocrinological investigation · 2017Article
- Neuron-Specific Enolase as an Immunohistochemical Marker Is Better Than Its Reputation.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2017Article
- Fatal Systemic Vasoconstriction in a Case of Metastatic Small-Intestinal NET.Case reports in gastrointestinal medicine · 2017Article
- Serum chromogranin A levels for the diagnosis and follow-up of well-differentiated non-functioning neuroendocrine tumors.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Neuroendocrine Cancer of Rectum Metastasizing to Ovary.Case reports in oncological medicine · 2016Article
- Hepatic arterial embolization in patients with neuroendocrine tumors.Journal of experimental & clinical cancer research : CR · 2014Review
- Stapling of the botulinum type A protease to growth factors and neuropeptides allows selective targeting of neuroendocrine cells.Journal of neurochemistry · 2013Article
- Clinical usefulness of plasma chromogranin a in pancreatic neuroendocrine neoplasm.Journal of Korean medical science · 2013Article
- Postpartum hypercalcemia secondary to a neuroendocrine tumor of pancreas; a case report and review of literature.Iranian journal of medical sciences · 2011Article
- Telomerase and the endocrine system.Nature reviews. Endocrinology · 2011Review
- Multimodal management of neuroendocrine liver metastases.HPB : the official journal of the International Hepato Pancreato Biliary Association · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroendocrine tumors (NET) may originate in different organs, from cells embryologically different but expressing common phenotypic characteristics, such as: the immuno-reactivity for markers of neuroendocrine differentiation (defined as "pan-neuroendocrine"), the capacity to secrete specific or aspecific peptide and hormones and the expression of some receptors, that are at the basis of the current diagnostic and therapeutical approach, peculiar to these tumors. NET have been conventionally distinguished in functioning, when associated with a recognized clinical endocrine syndrome, and non-functioning. However, this terminology may be misleading, since the great majority of NET may secrete neuroendocrine peptides, which can be employed as clinical markers for both diagnosis and follow-up. On the other hand, tissue immuno-reactivity for specific hormones does not always reflect secretory activity of the tumor cells. Finally, receptors and genetic markers are acquiring a relevant role in the characterization of NET, both improving knowledge of biology and physiopathology of NET, as well as in developing specific strategies to establish an early diagnosis and targeted therapies, to adopt prophylactic strategies in familial forms, and to identify more efficacious targets for therapy in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.